Drug collection nationwide spread drug companies to reduce prices fight began?

Drug collection policies around the continued promotion or brewing, pharmaceutical companies are also in varying degrees of independent price reduction, the market under the general trend will undoubtedly be more intense.
On June 26, Hebei officials announced their entry into the Bureau to follow up on the national volume procurement. Judging from the current wind, a new round of centralized procurement will soon be carried out in different ways throughout the country.1, Hebei officially followed the standard
recently in the centralized procurement of frequent action.
On June 25, Hebei Province Pharmaceutical Centralized Procurement Network announced that BMS promised to supply Fusinpri sodium tablets (10mg x 14 tablets) at selected prices in Hebei for centralized procurement of national drugs, but due to insufficient capacity to meet Hebei procurement demand, Hebei publicly selected new manufacturers to meet procurement standards to supply.
And soon the next day, the baton picker was in place. On June 26, Hebei Province Pharmaceutical Centralized Procurement Network announced that, after negotiations and consultations between the two sides, Huahai Pharmaceuticals with the specifications of Fusinpri sodium tablets in Hebei to implement the national centralized procurement of the selected price, and has the supply capacity. This also means that Hebei's 2018 Fusinpri sodium tablets (10mg x 14 tablets) 60% of the use of the share was successfully won by Huahai.
At the same time, Hebei officially announced the entry into the bureau to follow up the national volume procurement. Hebei Province on the same day published "on the national centralized procurement of selected drugs with the generic name of the production enterprises quoted notice" and "on the centralized procurement with the state of selected drugs with the generic name of the production enterprises to confirm the list price notice", clearly indicated that Hebei will follow up on July 1 to implement the national centralized procurement of drugs.
Hebei will confirm the price of the national centralized procurement of selected drugs with the generic name of the production enterprise. All drugs included in the "Hebei Province follow-up national centralized procurement of selected drugs with the generic name quotation directory" can be quoted, the authorized person from June 26 to June 28 at 17:00 to submit the quotation to Hebei Province medical drug equipment centralized procurement center.
Hebei stressed that the enterprise promised that the drug price should not be higher than the price negotiated with the generic name Shanghai and other provinces and cities in the country the lowest winning bid / hanging network price, where above the above two quotations will be cancelled.
Hebei Province has also published the corresponding reimbursement principles: if the price of the un selected drug is higher than the price of the drug selected under the same generic name, the proportion of the individual's prior burden shall be increased by 10% on the basis of the linkage with the price of the generic name;
2, the national spread of the ragingfrom the current trend can be seen, although the second batch of national drug centralized procurement program has not yet officially fallen hammer, but all over and enterprises have long been unable to sit.
Recently, Hu Jinglin, director of the National Health Insurance Administration, pointed out the priorities of the Health Insurance Bureau in a speech at the Boao Forum for Asia Global Health Forum, including "focusing on the inflated prices of pharmaceutical supplies, promoting the pilot procurement and use of drug agencies organized by the state", and "playing the guiding role of medical insurance, accelerating the reform of payment methods, improving the dynamic adjustment mechanism of the health insurance catalogue, and promoting the application of better and more valuable medicines and medical technologies at affordable prices". From his statement, it can be dedist from the "centralized procurement" and "drug price" between the two points.
On June 26, the National Health and Health Commission held a conference on the typical experience of the pilot provinces of comprehensive medical reform in Toning, Anhui Province. Referring to solving the problem of "expensive medical care", Liang Wan-year, Director of the Medical Reform Department of the Health and Health Commission, pointed out that the pilot provinces had taken drug reform as a breakthrough and deepened the linkage between the three doctors, and that the first lesson he shared was to "further reduce the inflated drug prices". The pilot provinces are actively implementing reform measures such as the national basic drug system and centralized procurement, so as to squeeze out the water of the inflated prices of medicines." And this also releases a signal that the concentration of procurement around or will soon land, pharmaceutical companies in this trend how to seize the market ahead of time, it is necessary to pay close attention to the local market trends and put on the agenda.
Since the end of May, many provinces and cities have officially started to follow up the national harvest or are preparing to follow up the national harvest, and the recent can see a clear trend of expansion.
Fujian became the first province to formally follow suit. On January 30, This year, Fujian Province organized a follow-up to the national collection and use of the symposium, put forward the 4 plus 7 belt volume procurement of selected products can enjoy direct access to 60% of Fujian Province's procurement base and other benefits. Subsequently, by the end of May, Fujian Province fully implemented the implementation plan to follow up the national organization of centralized drug procurement and use of the pilot work, Fujian officially followed up the national collection, on June 1st, the province's public medical institutions began to purchase 25 winning varieties.
At the end of May, the document "Qinghai Province 2019 drug centralized procurement and implementation plan" outflow, the content shows that the province's medical institutions will be implemented in Qinghai Province, planned to start in June 2019, the procurement of drugs will not be limited to the 4 plus 7 selected products.
Shandong Provincial Health Insurance Bureau issued a notice on June 13, will carry out joint procurement of drugs in public medical institutions. The notice requires Jinan, Qingdao, Yantai, Weihai, Tai'an, Nizhao and other cities to carry out pilot projects first, and select some of the pilots to start the first batch of joint drug procurement by the end of July.
On June 26, Shandong Provincial Health Insurance Bureau, Provincial Health And Wellness Commission and Provincial Public Resources Trading Center jointly issued the Notice on the Survey and Statistics of Some Drug Use Data of Public Medical Institutions, which requires public medical institutions in the province to organize drug centralized procurement and use in 26 countries to count their 2017 and 2 018 usage, and forecast usage from October 1, 2019 to September 30, 2020, forecast usage in principle is not lower than the 2017 and 2018 annual average, July 1 to complete the report.
Previously, Jiangxi, Henan and Inner Mongolia have similar statistical reports of the outflow of documents, indicating that in preparation for the implementation of the collection. Recently, the industry also has Hunan, Wuxi, Jiangsu and other places with the standard document outflow.
On the one hand, all over the country in order to follow up the intensive procurement preparation, on the other hand, pharmaceutical companies are also actively in this large plate layout.
East China Pharmaceutical production of Akapo sugar chewing tablets recently in Heilongjiang, Hainan, Guizhou to apply for independent price reduction. A box (50mg x 30 tablets) of Akapo sugar chewing tablets in Hainan from 80.7 yuan to 46.7 yuan, in Heilongjiang from 80.5 yuan to 43.46 yuan, Guizhou from 80.50 yuan to 42.82 yuan. There are currently no follow-up signals in all three regions. According to statistics, Akapo sugar in 2018 in China's public medical institutions terminal sales reached 8.406 billion yuan, mainly Bayer, East China Pharmaceuticals, Green Leaf Pharmaceuticals three occupied the market, of which chewing tablets for Akapo sugar exclusive dosage form.
In addition, the popular anti-cancer drugs to the recent price reduction of the dosamine is also very high- and high-profile. On June 6, Shanghai Sunshine Pharmaceutical Purchasing Network announced a price reduction for Qilu-Lanadamine, whose amine capsules (25mg, 21 capsules/box) were reduced to 3,980 yuan, 1,400 yuan lower than the lowest purchase price of the previously announced health insurance payment agreement. On the 14th, Shandong Province drug centralized procurement announced a new batch of anti-cancer drug price reduction information, which shows that Zhengda Tianqing the same specifications of the same size to the amine capsule from the original 5380 yuan to 3950 yuan, a drop of 26.6%. On June 21st, Zhengda Sunny and in Anhui Province independently lowered the price of the amine capsule, also adjusted to 3950 yuan.
Drug collection policies around the continuous promotion or brewing, pharmaceutical companies are also in varying degrees of independent price reduction. There is no doubt that the market competition under the general trend will be more intense. (E drug manager)